Company intelligence / Profile preview

Lapharm

Rosenheim, Bavaria, Germany

Ownership: Private
Employees: ~15
Development stage: Other

Overview

Lapharm GmbH Pharmazeutische Produkte was a German pharmaceutical company based in Rosenheim, Germany, specializing in the distribution of oncology products and medical technologies. The company provided various oncology therapeutics, such as paclitaxel and vinorelbine, and entered into a notable agreement to provide an exclusive distributorship for a hydrogel-based tissue spacer (CS Protect-Hydrogel) used in radiation therapy for prostate cancer. Lapharm was subsequently merged into CS Diagnostics Pharma GmbH and no longer operates as an independent entity.

Therapeutic areas: Oncology
Modalities: Small moleculeDevice
Industry: Biotech

Partnerships

CS Diagnostics

Beyond the preview

Go deeper on Lapharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lapharm.

Explore the full profile